Adnexus Therapeutics Announces Issuance Of U.S. Patent For Broad Protection Of New Therapeutic Class, Adnectins(TM)

WALTHAM, Mass.--(BUSINESS WIRE)--Adnexus TherapeuticsTM, Inc. announced today that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 7,115,396 with broad composition of matter claims to AdnectinTM proteins. Exclusively owned by Adnexus, this patent further expands the company’s ownership of Adnectins, a class of targeted biologics with broad applicability across many aspects of the biotechnology industry, including both therapeutics and diagnostics.